AtaiBeckley (ATAI) investor relations material

Key regulatory and political developments

• Recent executive order directed the FDA to accelerate psychedelic drug approvals, with priority vouchers issued to three companies, expediting regulatory timelines.

• Companies are preparing for earlier-than-expected approvals, with commercial teams and launch strategies in place for potential market entry by year-end.

• FDA engagement has been constructive, with consistent support and Breakthrough Therapy Designations, but inter-agency coordination with the DEA remains a challenge.

• The scheduling process for these drugs is established but may benefit from parallel FDA-DEA review to streamline access.

Clinical development and trial design

• Multiple companies are advancing late-stage trials for various psychedelic compounds targeting depression and anxiety, with pivotal data readouts expected this year.

• Rigorous clinical standards are being applied, with robust trial designs and central raters to address concerns like functional unblinding.

• Functional unblinding is not unique to psychedelics and is managed through established trial methodologies.

• Efficacy benchmarks focus on statistically significant and clinically meaningful results, with effect size and durability as key differentiators.

• Transition from Phase II to Phase III trials involves managing increased variance and ensuring generalizability without compromising efficacy.

Commercialization and market differentiation

• Infrastructure for interventional psychiatry has expanded rapidly, with thousands of centers now able to deliver these treatments.

• Differentiation will depend on factors like duration of effect, ease of administration, and patient/provider experience.

• Short-duration compounds that fit existing treatment paradigms are seen as advantageous.

• Market heterogeneity suggests multiple drugs can succeed, addressing diverse patient needs.